دورية أكاديمية

Clinical Progression of High-Grade Cervical Intraepithelial Neoplasia: Estimating the Time to Preclinical Cervical Cancer From Doubly Censored National Registry Data.

التفاصيل البيبلوغرافية
العنوان: Clinical Progression of High-Grade Cervical Intraepithelial Neoplasia: Estimating the Time to Preclinical Cervical Cancer From Doubly Censored National Registry Data.
المؤلفون: Vink, Margaretha A., Bogaards, Johannes A., van Kemenade, Folkert J., de Melker, Hester E., Meijer, Chris J. L. M., Berkhof, Johannes
المصدر: American Journal of Epidemiology; Oct2013, Vol. 178 Issue 7, p1161-1169, 9p
مصطلحات موضوعية: PAPILLOMAVIRUS disease diagnosis, CERVIX uteri tumors, CERVICAL intraepithelial neoplasia, CONFIDENCE intervals, REPORTING of diseases, GENES, PAPILLOMAVIRUSES, PROBABILITY theory, RESEARCH funding, TIME, DISEASE progression, STATISTICAL models, EARLY detection of cancer, DIAGNOSIS
مصطلحات جغرافية: NETHERLANDS
مستخلص: Little is known about the time span of progression from high-grade cervical intraepithelial neoplasia (CIN2/3) to invasive cervical cancer. Estimation of this duration from longitudinal studies is not permitted, as CIN2/3 should be treated when detected. Cross-sectional data on the age-specific incidence of detected CIN2/3 and cervical cancer cases are readily available in national registries, but these data are difficult to interpret because neither the moment of lesion development nor the onset of invasive cancer is observed. We developed a statistical model for estimating the duration of time between CIN2/3 and preclinical cancer using Dutch national registries for the years 2000–2005. Human papillomavirus (HPV) genotype data were used to separate CIN2/3 and cancer incidences to obtain estimates for HPV-16-positive and HPV-16-negative lesions. The median time from CIN2/3 to cancer was estimated to be 23.5 years (95% confidence interval: 20.8, 26.6), and 1.6% of the lesions progressed to cancer within 10 years. The median duration for HPV-16-positive lesions was similar, but 2.4% of the HPV-16-positive lesions progressed to cancer within 10 years, as compared with 0.6% for HPV-16-negative lesions. Estimated durations of time to cancer are essential for reassessment of the optimal screening interval in light of vaccination and novel screening tests. [ABSTRACT FROM PUBLISHER]
Copyright of American Journal of Epidemiology is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:00029262
DOI:10.1093/aje/kwt077